MS Speaks

Multiple Sclerosis => TREATMENTS => Topic started by: agate on May 11, 2019, 02:32:11 pm

Title: (AAN abst.) Impact of Tysabri switch to moderate vs. high-efficacy DMT
Post by: agate on May 11, 2019, 02:32:11 pm
Abstract of a paper presented at the annual AAN conference (Philadelphia, May 4-10, 2019) by researchers at the Cleveland Clinic entitled "Early Impact of Natalizumab Switch to Moderate Versus High Efficacy Disease Modifying Therapy in Clinical Practice":


http://indexsmart.mirasmart.com/AAN2019/PDFfiles/AAN2019-000892.pdf